Skip to main content
. 2019 Sep 11;48:169–177. doi: 10.1016/j.ebiom.2019.08.067

Fig. 4.

Fig. 4

CXCR3-mediated signaling is required for anti-PD-1 therapy. (a) Tumor volumes were observed for 23 days and presented in a line chart (n = 12). (b) Tumor volumes were observed for 29 days and presented in a line chart (n = 7). (c–e) The cytometry analysis of CXCR3+ T cells in tumor from different treatment groups. (mean ± s.e.m.; n = 3, *P < 0.05, **P < 0.01 and ***P < 0.001 by Student's t-tests).